Denali Therapeutics Inc. (DNLI) Free Cash Flow
Denali Therapeutics Inc. (DNLI) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2018-12-31 | $46.72M |
| 2019-12-31 | -$169.50M |
| 2020-12-31 | $413.06M |
| 2021-12-31 | -$219.89M |
| 2022-12-31 | -$262.55M |
| 2023-12-31 | -$370.93M |
| 2024-12-31 | -$363.61M |
| 2025-12-31 | -$422.10M |
How DNLI compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| REPL | Replimune Group Inc. | -$284.57M |
| IOVA | Iovance Biotherapeutics Inc. | -$336.24M |
| AGIO | Agios Pharmaceuticals Inc. | -$377.29M |
| NTLA | Intellia Therapeutics Inc. | -$395.87M |
| RARE | Ultragenyx Pharmaceutical Inc. | -$487.00M |
These are five companies in the same sector as DNLI with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Denali Therapeutics Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("DNLI", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | DNLI | $24.57 | -1.44% | 0.77M |
| 3 | ||||
| 4 | ||||
| 5 |